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Abstract
Background: Informed decision making is the theoretical basis in the UK fo r men's decisions 
about Prostate Specific Antigen (PSA) testing fo r prostate cancer testing. The aim o f this study is 
to  evaluate the effect o f a web-based PSA decision-aid, Prosdex, on informed decision making in 
men. The objective is to  assess the effect o f Prosdex on six specific outcomes: (i) knowledge o f PSA 
and prostate cancer-related issues -  the principal outcome o f the study; (ii) attitudes to  testing; (iii) 
decision conflict; (iv) anxiety; (v) intention to  undergo PSA testing; (vi) uptake o f PSA testing. In 
addition, a mathematical simulation model o f the effects o f Prosdex w ill be developed.
Methods: A  randomised controlled tria l w ith four groups: tw o  intervention groups, one viewing 
Prosdex and the other receiving a paper version o f the site; tw o  control groups, the second 
controlling fo r the potential Hawthorn effect o f the questionnaire used w ith the first control group. 
Men between the ages o f 50 and 75, who have not previously had a PSA test, w ill be recruited from 
General Practitioners (GPs) in Wales, UK. The principal outcome, knowledge, and four other 
outcome measures -  attitudes to  testing, decision conflict, anxiety and intention to  undergo testing 
-  w ill be measured w ith an online questionnaire, used by men in three o f the study groups. Six 
months later, PSA test uptake w ill be ascertained from  GP records; the online questionnaire w ill 
then be repeated. These outcomes, and particularly PSA test uptake, w ill be used to  develop a 
mathematical simulation model, specifically to  consider the impact on health service resources.
T ria l registration: C urrent Controlled Trial: ISRCTN48473735.
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Background
Prosdex is a web-based decision aid to help m en consider 
whether or no t to have a Prostate Specific Antigen (PSA) 
test, potentially for prostate cancer [1]. It was developed in 
the context of the UK Prostate Cancer Risk Management 
Programme (PCRMP), a strategy, promoted by the UK 
National Cancer Screening Programme, which has, as one 
of its key goals, the prom otion of informed decision mak­
ing about PSA testing [2]. According to the strategy, men 
should only have a PSA test if they have received appropri­
ate information and had the opportunity to make a deci­
sion -  a decision which, for many, is difficult due to the 
uncertainty of prostate cancer testing. Despite its increas­
ing incidence in men, the only widely-available test for 
prostate cancer, PSA, is limited not only by its poor sensi­
tivity and specificity, but also by the uncertainty relating 
to the natural history and the management of the disease 
[2,3]. It is for these reasons that, unlike the USA, there is 
not a PSA screening programme in the UK. Moreover, the 
PCRMP strategy arguably reflects the tension between an 
evidence-based approach to population testing -  PSA in 
this case -  and the needs of individual m en to make 
informed decisions about their own health.
Decision aids have been developed for a range of health 
conditions to facilitate informed decision making. Char­
acteristically, the risks and benefits of different options are 
presented in a variety of formats and media, thereby help­
ing patients in the process of values clarification, seen as 
fundamental for informed decision making. Prosdex was 
developed in 2002-04, supported by a grant from Cancer 
Research UK and the NHS Cancer Screening Programme 
[1]. Hosted by Cardiff University, with links from NHS 
Direct Online and Cancer Research UK, it presents evi­
dence-based information about prostate cancer and PSA 
testing, encouraging users to weigh the pros and cons of 
testing for themselves. In addition, Prosdex includes video 
clips of enacted patient experiences about the PSA test and 
subsequent investigations/treatments. There is also infor­
mation about 'shared decision making' and, through 
structured decision support (the 'decision stacker'), Pros- 
dex aims to actively encourage informed decision making.
The aim of this proposed study is to evaluate the effect of 
Prosdex on informed decision making. In order to do so, a 
range of outcome measures need to be considered, due to 
the fact that a specific measure of informed decision mak­
ing in PSA testing has not been developed. Three of the 
proposed outcome measures -  knowledge, attitude to 
testing, and test uptake -  are constituents of an informed 
decision making measure in another health context, pre­
natal Down syndrome [4]. These, and the other three pro­
posed outcome measures -  decision conflict, anxiety and 
intention to undergo testing -  have been used in evalua­
tions, specifically randomised controlled trials, of other
PSA decision aids. In a systematic review of these trials, we 
found that knowledge increased by 19.5% and PSA testing 
decreased by 3.5% [5]. The six proposed outcome meas­
ures will, therefore, no t only allow an assessment of the 
effect of Prosdex on informed decision making, bu t also 
will allow comparisons with other evaluations of PSA 
decision aids. This will hopefully enable an appraisal of 
implementation issues, for example the degree of aware­
ness of the complexity surrounding PSA testing engen­
dered in users by Prosdex[6]. Finally, a mathematical 
simulation model, using data from the trial, will allow 
extrapolations of the potential effects of Prosdex on health- 
service resource use, for example the impact on urological 
services, and on health outcomes.
Methods
i) Design
randomised controlled trial (RCT). This allows a compar­
ison of the effect of a single intervention (Prosdex) on the 
specified outcomes in the objectives. The design employs 
four randomised groups of m en in order to distinguish 
the effects of Prosdex from two other possible effects: for­
m at (electronic versus written), and the Hawthorne effect, 
specifically the effect that participating in a clinical trial 
could have on subsequent PSA uptake. RCTs have been 
used successfully to evaluate the effects of other PSA deci­
sion aids in North America [7,8].
ii) Setting
Wales. Men recruited using GP lists.
iii) Participants
a) Inclusion criteria
Men between 50 and 75 will be invited to participate, as 
prostate cancer is rare below the age of 50;[2] also, above 
the age of 75, m en would be less likely, in our opinion, to 
complete the study, particularly the online questionnaire 
element. The men will access the study via the internet 
and must be able to use a computer. They will be asked to 
indicate this on the consent form. The numbers unable to 
participate due to this, in addition to those who fail to 
respond to the invitation, will be counted separately, in 
line with the CONSORT guidelines for reporting RCTs [9].
b) Exclusion criteria
Men who cannot read English will be excluded, as Prosdex 
was developed first only in English. Also excluded will be 
men who are known to have had prostate cancer and 
those whose GP records indicate that they have had a PSA 
test.
c) Recruitment process
Suitable m en will be identified by GPs, in Wales, who will 
also send the invitation letters, participant information 
sheets (PIS) and consent forms. A member of the practice
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staff, probably the data manager, will be asked to identify 
men, aged 50-75, who have not had a PSA test. Using that 
generated list, the data manager will be asked to select 100 
m en using a serial recruitment process based on the date 
of the m onth of the men's birthdays: that is, the first m an 
selected will be the first m an on the list with a birthday 
01/month/year; second man, 02/month/year; and so 
forth up to 31 when the process will be repeated until 100 
m en are selected. A member of the practice staff who has 
knowledge of the patients -  Practice Manager or GP -  will 
then be asked to screen the list for m en who, in their opin­
ion, are unsuitable for the trial due to serious ill-health. 
The number of m en thus removed will be reported.
Affirmative consent forms from each practice will be 
transferred to the research officer who, in turn, will allo­
cate each participant from that practice with a number 
provided the by trial statistician who will oversee the allo­
cation process. Accordingly, the participants will be ran­
domly allocated, by computer, to one of two intervention 
groups or to one of two control groups. This process will 
occur remotely in order to secure concealment. For each 
practice, the statistician will allocate 80 numbers, gener­
ated in 'blocks', the number for which will be between 12 
and 16 in order to guarantee 'balance'. Randomisation 
will occur at the level of the m an as we are interested in 
individual decision-making outcomes, and there is 
unlikely to be a significant intra-cluster correlation for 
these outcomes [10]. There will be no randomisation of 
the GP practices, but they will be stratified according to 
socio-economic groups, with an aim of 4 different such 
groups. After the collection of the data, there will be social 
analysis of these groups.
iv) Intervention (see fig 1)
A specific version of the Prosdex website will be developed: 
it will require a password for access and will generate the 
online questionnaire. Men in intervention group 1 will be 
asked to log onto and view the website, either in their own 
homes or in another setting of their choice. The second 
intervention group (2) will receive a paper document 
comprising the text of the website. This enables evaluation 
of the Prosdex features (e.g. video clips and the structured 
decision support) that go beyond the mere presentation 
of the text content. In the first control group (A), men, 
after inserting their password, will be asked to complete 
the online questionnaire without viewing Prosdex. The sec­
ond control group (B) will not initially be given the 
details of the study website.
There are, therefore, two main comparisons:
1) Intervention Group 1 v Control Group A:
Prosdex (+ online questionnaire) against no intervention, 
bu t with the online questionnaire: tests the effect of Pros- 
dex content itself within the online context.
2) Intervention Group 1 v Intervention Group 2:
Two different formats to present almost identical content: 
tests the effects of the media: online versus paper-based.
The comparison between Control Group A and Control 
Group B allows a consideration of the Hawthorne effect of 
the questionnaire on PSA testing, to aid interpretation of 
outcomes in Intervention Groups 1 & 2.
At the six m onth stage, after the ascertainment of PSA test­
ing status, m en in the two intervention groups and control 
group A will be asked to repeat the online questionnaire. 
The purpose of repeating the questionnaire will be to eval­
uate any changes in the outcomes over time. O f particular 
interest is the effect on the principal outcome, knowledge, 
thereby allowing an assessment of knowledge retention. 
Men in control group B will also be asked at the six month 
stage to complete the online questionnaire in order to 
provide a control for the other three groups. All the men, 
therefore, at this six m onth stage, will be sent a letter ask­
ing them to access and complete the online questionnaire. 
This second questionnaire will have an additional ques­
tion asking m en to indicate, by 'left-clicking' on corre­
sponding boxes, any types of information, newspapers/ 
magazines for instance, they may have used in reaching a 
decision about how likely they are to have a PSA test.
v) Outcomes
Six outcomes will be measured in this study: (a) knowl­
edge of PSA and prostate cancer-related issues -  this is the 
main outcome of the study, on which the sample size cal­
culation is based; (b) attitudes to testing; (c) decision con­
flict; (d) anxiety; (e) intention to undergo PSA testing; (f) 
uptake of the PSA test. Outcomes (a) -  (e) will be gathered 
from the online questionnaire. In addition to these out­
comes, based on these results, a mathematical simulation 
model of the effects of Prosdex on subsequent resource use 
and health outcomes will also be developed. This model 
will be based on the results of the trial.
a) Knowledge o f PSA and prostate cancer-related issues 
Knowledge will be the principal outcome of this study. 
Previous randomised controlled trials of PSA decision 
aids have used knowledge as their principal outcome, and 
in our systematic review of these trials we found that PSA 
decision aids resulted in an improvement in knowledge of 
19.5% [11]. Knowledge will be assessed using a set of 
knowledge questions, used in our earlier evaluation of a 
brief paper-based leaflet about PSA testing,[12] which
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showed an ability to discriminate between intervention 
and control groups.
b) Attitudes to testing
This will use a 12-item scale developed and used in  the 
same evaluation of a brief paper-based leaflet about PSA 
testing [12].
c) Decision conflict [13 ]
This scale measures patients' confidence or uncertainty 
('conflict') about whether they feel their choice is the best 
for them personally. It has acceptable validity and reliabil­
ity (internal consistency alpha coefficients range from 
0.78 -  0.89; test-retest reliability coefficients exceed 0.80) 
[14]. Given the nature of the decision about having a PSA
test, with a high degree of uncertainty likely to affect deci­
sion making, it is important to use this, the most widely 
used outcome measure in decision aid studies [15].
d) Anxiety
This will be assessed using the short form Spielberger 
questionnaire for 'state' anxiety, validated and shown to 
be responsive in our earlier studies of shared decision 
making and risk communication [10].
e) Intention to undergo PSA testing
This will be assessed using a single item question, with 
Likert-like response scale, which has also been used in our 
earlier evaluation of a brief paper-based leaflet about PSA 
testing [12].
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f) Uptake o f the PSA test
This will be assessed at six months after the intervention. 
GPs who participate in the study will be asked to ascertain 
the men's PSA testing status for that six m onth period, 
from their records, and inform the research team whether 
or not the test was done. The GPs will be provided with 
specific forms for this purpose, to be returned to the 
research team. It is possible that m en may have had PSA 
tests elsewhere, such as via hospital clinics, but it is likely 
that these will be evenly distributed across the interven­
tion and control groups. Moreover, it may be less likely 
that these decisions to be tested were patient-led. Such 
'external' results, when they do occur, are increasingly 
recorded in GP records.
(vi) Comparisons and analysis
Comparability of the four groups for baseline characteris­
tics of age, ethnicity, marital status and education will be 
assessed. Outcomes will be compared between groups on 
an 'intention to treat' basis by standard statistical tests, 
including chi2 for categorical variables and t, Mann-Whit­
ney and one-way ANOVA tests for continuous and ordinal 
variables. Point and interval estimates for appropriate 
measures of effect size will be reported as well as p values. 
A clinically significant and relevant difference in the prin­
cipal outcome, knowledge, between the two groups, will 
be set at 20%. The statistical power for this study is aimed 
at 90%, assuming a type 1 error rate of 5%. The sample 
size will be 600 men: 150 in each of the four groups. This 
figure is derived from the findings of our systematic 
review of PSA decision aids where 4 RCTs (USA) were 
found to result in improved knowledge of 19.5% (SD 
45.1). Thus, 150 m en per group will allow the detection 
of a 20% absolute difference with over 90% power. 
Assuming a recruitment and completion rate of 30%, 
2000 m en will be invited from 20 GP practices, 100 men 
from each practice. For the Decisional Conflict Scale, a 
comparison of any 2 groups each of 150 subjects would 
detect a shift of 0.32 standard deviations, with power 80% 
at the conventional 5% alpha level. The data will be col­
lected in a SQL-server database, transferred to Excel, and 
then analysed using SPSS Syntax, and the results expressed 
with both p values and confidence intervals.
vii) M a th em atica l Simulation M o d e l
A mathematical simulation model of the effects of Prosdex 
on subsequent resource use and health outcomes will also 
be developed. This will use the trial outcomes, particularly 
PSA uptake, to model potential diagnoses and morbidity 
(drawing on existing best evidence [16]) and the resulting 
resource use and workload implications at GP practice 
and NHS Trust levels. For example, at GP practice level, 
the age distribution in a practice will be used, together 
with PSA take-up after the intervention, to estimate work­
loads and resource requirements, using appropriate sam­
pling distributions as in the investigator's previous 
research.[17,18] By further sampling of GP practices 
within a hospital Trust locality, estimates would be made 
of the implications at Trust level for urological and other 
services. The data will be obtained for local GP practices 
from our network of practices who have participated in 
several other research studies in recent years.
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